List Results
Refine Search
Results by Topic
Results on Map
Search Details
Found 4327 studies with search of: multiple sclerosis OR MS
Hide studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Active, not recruiting Far Infrared Irradiation for Managing and Treating Multiple Sclerosis (MS)
Condition: Multiple Sclerosis
Intervention: Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
2 Enrolling by invitation Comparison of Campath and Rebif Treatment on Cognition in Multiple Sclerosis (MS)
Condition: Relapsing Remitting Multiple Sclerosis
Intervention:
3 Recruiting Oral Cladribine in Early Multiple Sclerosis (MS)
Condition: Multiple Sclerosis
Interventions: Drug: Oral cladribine;   Drug: Placebo
4 Completed A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis (MS)
Condition: Relapsing Forms of Multiple Sclerosis
Interventions: Procedure: Plasma exchange;   Drug: natalizumab treatment
5 Recruiting Exploratory Study on the Timing of Multiple Sclerosis (MS) Symptoms
Condition: Relapsing Remitting Multiple Sclerosis
Intervention:
6 Completed Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention: Drug: Daclizumab
7 Recruiting Gene Expression Profiles in Multiple Sclerosis (MS)
Condition: Multiple Sclerosis
Intervention: Procedure: Blood Draw
8 Active, not recruiting Study of Fampridine-SR Tablets in Multiple Sclerosis Patients Who Participated in the MS-F203 Trial
Condition: Multiple Sclerosis
Intervention: Drug: Fampridine-SR
9 Completed Exploratory Study to Investigate the Reparative and Regenerative Potential of Alemtuzumab in Relapsing-Remitting Multiple Sclerosis Patients Participating in the CARE MS I and MS II Studies
Condition: Multiple Sclerosis
Intervention:
10 Active, not recruiting Mesenchymal Stem Cells for the Treatment of MS
Condition: Multiple Sclerosis
Intervention: Biological: injection of autologous stem cells
11 Completed Atorvastatin (Lipitor) Therapy in Patients With Clinically Isolated Syndrome (CIS) at Risk for Multiple Sclerosis
Condition: Multiple Sclerosis
Interventions: Drug: Atorvastatin;   Drug: Placebo
12 Recruiting Safety and Efficacy Extension Study of Daclizumab HYP to Treat Relapsing-Remitting Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention: Drug: Daclizumab HYP
13 Recruiting Low Fat Diet and Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Other: Low fat study diet
14 Completed Assessment of Patients With Multiple Sclerosis (MS)
Conditions: Herpesviridae Infection;   HTLV-I Infection;   Multiple Sclerosis;   Tropical Spastic Paraparesis;   Vasculitis
Intervention:
15 Recruiting Clinical 15 Months Study Comparing Monthly Pulse ACTH (Acthar Gel) Therapy With Monthly Methylprednisolone (MP, Solumedrol) for Multiple Sclerosis (MS) Patients Who Are on Regular Beta-interferons (Avonex, Betaseron or Rebif)
Condition: Multiple Sclerosis
Interventions: Drug: ACTH;   Drug: Methylprednisolone
16 Active, not recruiting Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (MS)CombiRx
Condition: Relapsing Remitting Multiple Sclerosis
Interventions: Drug: Interferon beta 1-a;   Drug: glatiramer acetate;   Other: placebo
17 Active, not recruiting The Effects of TYSABRI Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Biological: TYSABRI (natalizumab)
18 Recruiting Therapy Optimization in Multiple Sclerosis (MS)
Condition: Multiple Sclerosis
Intervention: Drug: Glatiramer Acetate, IFN-beta 1a (IM), IFN-beta 1a (Subcu), and IFN-beta 1b
19 Not yet recruiting Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing Remitting Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention: Drug: Daclizumab HYP
20 Active, not recruiting Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Biological: alemtuzumab;   Biological: interferon beta-1a (Rebif®)

Previous Page Studies Shown (1-20) Next Page (21-40)
Save this search by bookmarking this page.
When you use your bookmark, the search will be performed again on the most recent collection of studies.
RSS Feeds for studies found by your search that were:
  First received in the last 14 days,  
  Last updated (includes received) in the last 30 days
  Download Options




Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services